Clinical trial NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
Official title: A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Synovial Sarcoma
Soft Tissue Sarcoma
Keywords: Synovial Sarcoma
SMARB1-Null Tumors
CFT8634
Soft Tissue Sarcoma
Myoepithelial Carcinoma
Extraskeletal Myxoid Chondrosarcoma
Renal Medullary Carcinoma
Chordoma
Epithelioid Sarcoma
Lead sponsor: C4 Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2022-05-02
Enrollment: 49
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic therapy; have relapsed/refractory tumors; have unresectable or metastatic disease; and are not candidates for available therapies known to confer clinical benefit. The study will characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of CFT8634.

Detailed description: The study was intended to be Phase 1/2 trial but did not advance to Phase 2.

Eligibility criteria: Inclusion Criteria:

1. Subject (and legal guardian where applicable) is (are) willing and able to provide signed informed consent (or assent, where applicable) and can follow protocol requirements
2. Subject has histologically or cytologically confirmed synovial sarcoma or SMARCB1-null sold tumor that is relapsed/refractory, and unresectable or metastatic; the subject must not be a candidate for available therapies that are known to confer clinical benefit

   a. Phase 1: subject must have received ≥1 prior line of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting b. Phase 2: i. Arm A: subject must have received only 1-2 prior lines of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting ii. Arm B: subject must have received ≥1 prior line of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting
3. Subject must be:

   * ≥18 years of age (no minimum weight),
   * ≥16 and \<18 years old and weighs ≥50 kg,
   * ≥12 and \<16 years of age and weighs ≥40kg,
   * or ≥16 and \<18 years of age and weighs ≥40kg and \<50kg
4. Subject must be able to safely swallow capsules
5. Subject must have measurable disease as defined by RECIST v1.1
6. Subject must have Eastern Cooperative Oncology Group performance status ≤2 or Lansky performance scale (LK scale) ≥ 60
7. Subject must have adequate organ function, defined as:

   1. Bone marrow function: absolute neutrophil count ≥1.0 x 109/L independent of growth factor support for ≤7 days prior to first dose of study drug for granulocyte colony-stimulating factor and ≤14 days prior to first dose of study drug for peg-filgrastim; hemoglobin ≥8 g/dL independent of transfusion support for ≤7 days prior to first dose of study drug; platelet count ≥75 x 109 /L independent of transfusion support for ≤3 days prior to first dose of study drug
   2. Coagulation: Prothrombin time (PT)/international normalized ratio (INR) \<1.5x the upper limit of normal (ULN) and activated partial thromboplastin time (aPTT) \<1.5x ULN (unless the subject is receiving anticoagulant therapy and INR and partial PT/aPTT are within therapeutic range of intended use of anticoagulants)
   3. Liver function: total bilirubin ≤1.5x ULN (≤3.0x ULN for subjects with Gilbert's syndrome), aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0x ULN; except for subjects who have tumor infiltration of the liver, where ALT and AST ≤5x ULN
   4. Renal function: must have a creatinine clearance ≥60 mL/min (via Cockcroft-Gault equation, institutional standard, or measured)
   5. Cardiac function: baseline corrected QT interval using Fredericia's formula ≤470 ms (adolescents 12-17 years of age: ≤450 ms) and a left ventricular ejection fraction ≥50% evaluated via echocardiogram or multi-gated acquisition (MUGA) scan
8. Availability of archival tumor tissue sample or newly obtained core/excisional biopsy of a tumor not previously irradiated
9. A female subject may be eligible to participate if she is not pregnant or planning a pregnancy, not breastfeeding, and following protocol mediated guidance to avoid pregnancy
10. A male subject must have had a prior vasectomy and agree to use a condom during the treatment period and for at least 90 days after the last dose of study treatment
11. A male subject must refrain from donating sperm while taking CFT8634 and for 90 days post-last dose
12. A female subject must refrain from donating ova while taking CFT8634 and for 180 days after discontinuation
13. All subjects must refrain from donating blood and blood products while receiving study drug and for 30 days post-last dose

Exclusion Criteria:

1. Subject has had major surgery within 21 days prior to the planned first dose of CFT8634

   a. Minor surgery (eg, minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 21 days prior to first dose of CFT8634
2. Subject has received standard of care or investigational systemic anti-neoplastic therapy within 14 days or 5 half-lives, whichever is shorter, prior to the planned first dose of CFT8634
3. Subject has received radiation therapy within 14 days prior to the planned first dose of CFT8634
4. Prior treatment with BRD9 degrader
5. Subject has central nervous system (CNS) involvement (primary tumor or metastatic disease), except in the following circumstances:

   1. Subjects with previously treated brain metastases may be permitted to participate provided they are stable (without evidence of progression by imaging 14 days prior to the first dose of study drug and any neurologic symptoms have stabilized), have no evidence of new or enlarging brain metastases, and if they are taking corticosteroids, they are on stable or tapering doses for at least 7 days prior to first dose of study drug. Antiseizure therapy is permitted provided the medication is not otherwise excluded and seizures have been controlled for at least 28 days since the last antiseizure medication adjustment
   2. Subjects with asymptomatic brain metastases found on Screening magnetic resonance imaging (MRI) may be permitted to be entered into the study without prior radiation therapy to the brain if they do not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant
6. Subject has any evidence of a CNS bleed including intra-tumoral hemorrhage
7. Subject has known bleeding diathesis
8. Subject has impaired cardiac function or clinically significant cardiac disease (i.e. uncontrolled heart disease/hypertension, clinically significant arrythmias, unstable angina/myocardia infarction/stroke within 180 days prior to screening)
9. Subject with presence of inflammatory vascular disease or microangiopathy (eg, thrombotic microangiopathies, hemolytic uremic syndrome \[HUS\], atypical HUS)
10. Subject with known malignancy, other than study indication, that is progressing or has required treatment within the past 3 years

    a. Subject with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (i.e. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
11. Subject has received live, attenuated vaccine within 28 days prior to first dose administration
12. Subject with known history of human immunodeficiency virus (HIV) infection
13. Subject had a venous thrombosis within 14 days prior to first dose of study drug
14. Subject with gastrointestinal absorption issues (e.g., malabsorption syndrome or other illness that could affect oral absorption).
15. Concurrent administration of strong cytochrome P450 (CYP) 3A4 inhibitors and inducers, and multidrug resistance mutation 1 (MDR1) inhibitors.

Primary outcomes:
measure: Frequency and severity of AEs and serious adverse events (SAEs)
timeFrame: From screening until at least 30 days after completion of study treatment
measure: Number of subjects with changes between baseline and post-baseline safety assessments based on safety laboratory results graded by CTCAE v5.0
timeFrame: From screening until at least 30 days after completion of study treatment
measure: Frequency of dose interruptions and dose reductions
timeFrame: From first dose until end of treatment
measure: Incidence of dose limiting toxicities (DLTs)
timeFrame: From first dose until 28 days after first dose
measure: Overall Response Rate (ORR)
timeFrame: Up to approximately 24 months
Secondary outcomes:
measure: Plasma concentration of CFT8634 to characterize the pharmacokinetics (PK) parameters of CFT8634
timeFrame: At multiple time points up to approximately 24 weeks
measure: Asses dose proportionality assessment
timeFrame: At multiple time points up to approximately 24 weeks
measure: Assess the pharmacodynamics by percent reduction from baseline of target protein
timeFrame: At multiple time points up to approximately 24 weeks
measure: ORR
timeFrame: Up to approximately 24 months
measure: Duration of Response (DOR)
timeFrame: Up to approximately 24 months
measure: Progression Free Survival (PFS)
timeFrame: Up to approximately 24 months
measure: Overall Survival (OS)
timeFrame: Up to approximately 48 months
measure: Time to next treatment
timeFrame: Up to approximately 8 months
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope
state: California
city: Santa Monica
country: United States
facility: Sarcoma Oncology Research Center
state: California
city: Aurora
country: United States
facility: University of Colorado - Aurora Cancer Center
state: Colorado
city: Jacksonville
country: United States
facility: Mayo Clinic - Jacksonville
state: Florida
city: Iowa City
country: United States
facility: University of Iowa Hospital and Clinics
state: Iowa
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Clinic - Rochester
state: Minnesota
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
city: New York
country: United States
facility: David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
state: New York
city: New York
country: United States
facility: Columbia University
state: New York
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
References: